Europe Hla Typing Transplant Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
 예측 기간 |
2021 –2028 |
 시장 규모(기준 연도) |
USD 194.35 Million |
 시장 규모(예측 연도) |
USD 344.87 Million |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
>유럽 이식을 위한 인간 백혈구 항원(HLA) 유형 검사 시장, 부산물 및 서비스(시약 및 소모품, 기기, 소프트웨어 및 서비스), 기술(시퀀싱 기반 분자 검사, 분자 검사 기술, 비분자 검사 기술), 이식 유형(고형 장기 이식, 조혈 줄기 세포 이식), 응용 분야(진단 응용 프로그램, 연구 응용 프로그램), 최종 사용자(독립 참조 실험실, 병원 및 이식 센터, 연구 실험실 및 학술 기관), 국가(영국, 프랑스, 이탈리아, 스페인, 스위스, 러시아, 네덜란드, 터키, 벨기에 및 기타 유럽 국가) 산업 동향 및 2028년까지의 예측.
시장 분석 및 통찰력: 유럽 인간 백혈구 항원(HLA) 이식용 타이핑 시장
유럽 인간 백혈구 항원(HLA) 이식 타이핑 시장은 2021년부터 2028년까지의 예측 기간 동안 상당한 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 유럽 인간 백혈구 항원(HLA) 이식 타이핑 시장이 2021년부터 2028년까지의 예측 기간 동안 7.8%의 CAGR로 성장하고 있으며 2020년의 1억 9,435만 달러에서 2028년까지 3억 4,487만 달러에 도달할 것으로 예상된다고 분석했습니다. 장기 이식 시술에 대한 수요 증가는 글로벌 인간 백혈구 이식 타이핑 시장 성장을 견인하고 있습니다.
인간 백혈구 항원(HLA) 타이핑은 골수 또는 제대혈 이식을 위해 환자와 기증자를 매치하는 데 사용됩니다. HLA는 신체의 대부분 세포에서 발견되는 단백질 또는 마커입니다. 면역 체계는 이러한 마커를 사용하여 어떤 세포가 신체에 속하고 어떤 세포가 신체에 속하지 않는지 인식합니다.
연구에 따르면 기증자는 최소 6개의 HLA 마커와 일치해야 합니다. 여러 번 더 가까운 일치가 필요합니다. 가장 좋은 일치는 자세한 검사를 통해 발견됩니다. 일부 HLA 유형은 다른 유형보다 흔하기 때문에 일부 환자는 일치하는 기증자를 찾는 데 더 큰 어려움을 겪을 수 있습니다. 일부 HLA 유형은 특정 인종 및 민족 그룹에서 더 자주 발견됩니다.
기증자와 환자의 HLA 마커 간의 밀접한 일치는 성공적인 이식 결과에 필수적입니다. HLA 일치는 새로운 건강한 혈액 세포의 성장과 발달(이식이라고 함)을 촉진하고 이식편 대 숙주(GVHD) 질환 이라고 하는 이식 후 합병증의 위험을 줄입니다 .
장기 기증에 대한 높은 수요, 혁신 및 기술 증가, 새로운 제품 출시도 이식을 위한 유럽 인간 백혈구 항원(HLA) 유형 분석 시장 성장을 촉진하고 있습니다.
A growing number of people are affected with by the HLA disorders which demand highly effective and advanced treatment to minimize the risk during the treatment. The healthcare systems need highly advanced drugs for numerous different types of HLA disorders during the treatment of patients. Therefore, the major market players are highly focusing on product launches and product approvals. Additionally, the government and regulatory bodies are supporting market players by virtue of product approval.
Rising product launches is acting as an opportunity for this market and is expected to impel the market growth for boosting the demand of global human leukocyte typing for transplant market.
Research on the human leukocyte antigen (HLA), is an extensively studied molecule involved in immunity and NGS technologies have revolutionised HLA typing procedure by providing fast and cost-effective technology. It is expected that lack skilled professionals is the major key challenge for the future growth of global human leukocyte antigen (HLA) typing for transplant market.
Europe human leukocyte antigen (HLA) typing for transplant market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Europe Human Leukocyte Antigen (HLA) Typing for Transplant Market and Market Size
Europe human leukocyte antigen (HLA) typing for transplant market is segmented on the basis of products and services, technology, transplant type, application, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of by products and services, Europe human leukocyte antigen (HLA) typing for transplant market is segmented in reagents and consumables, instruments, software and services. In 2021, instruments segment is expected to dominate the market due to high demand for organ transplantation that has rapidly increased.
- On the basis of technology, Europe human leukocyte antigen (HLA) typing for transplant market is molecular assay technologies and non- molecular assay technologies. In 2021, molecular assay technologies segment is expected to dominate the market due to rising awareness about the disease.
- 이식 유형을 기준으로, 유럽 인간 백혈구 항원(HLA) 이식 시장은 고형 장기 이식과 조혈모세포 이식으로 세분화됩니다. 2021년에는 고형 장기 이식 부문이 표적 인구 사이에서 이 질병 유형의 유병률이 증가함에 따라 시장을 지배할 것으로 예상됩니다.
- 적용을 기준으로, 이식을 위한 유럽 인간 백혈구 항원(HLA) 타이핑 시장은 진단 응용 프로그램과 연구 응용 프로그램으로 세분화됩니다. 2021년에는 진단 응용 프로그램 부문이 암과 유전 질환을 앓고 있는 환자의 수가 많기 때문에 시장을 지배할 것으로 예상됩니다.
- 최종 사용자를 기준으로, 이식을 위한 유럽 인간 백혈구 항원(HLA) 타이핑 시장은 독립적인 참조 실험실, 병원 및 이식 센터, 연구 실험실 및 학술 기관으로 세분화됩니다. 2021년에는 주요 시장 참여자들의 제품 출시가 증가함에 따라 병원 및 이식 센터 부문이 시장을 지배할 것으로 예상됩니다.
유럽 인간 백혈구 항원(HLA) 이식 시장 국가 수준 분석
이식을 위한 유럽 인간 백혈구 항원(HLA) 타이핑 시장을 분석하고, 국가, 제품 및 서비스, 기술, 이식 유형, 응용 프로그램 및 최종 사용자를 기반으로 시장 규모 정보를 제공합니다.
유럽 인간 백혈구 항원(HLA) 타이핑 이식 시장 보고서에서 다루는 국가는 독일, 프랑스, 영국, 헝가리, 이탈리아, 스페인, 러시아, 터키, 벨기에, 네덜란드, 스위스 및 기타 유럽 국가입니다.
영국은 이 지역에 대한 정부 지원금 증가로 인해 유럽 이식 시장을 장악할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 유럽 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
유럽 이식용 인간 백혈구 항원(HLA) 타이핑 시장에서의 의료비 증가와 혁신 및 기술 확대는 유럽 이식용 인간 백혈구 항원(HLA) 타이핑 시장 참여자들에게 새로운 기회를 창출하고 있습니다.
이식을 위한 유럽 인간 백혈구 항원(HLA) 타이핑 시장은 2011년~2019년 기간 동안 유럽 인간 백혈구 항원(HLA) 타이핑 시장 판매와 유럽 인간 백혈구 항원(HLA) 타이핑 시장 발전의 영향, 유럽 인간 백혈구 항원(HLA) 타이핑 시장을 지원하기 위한 규제 시나리오의 변화 등 특정 산업의 모든 국가별 시장 성장에 대한 자세한 시장 분석을 제공합니다.
경쟁 환경 및 유럽 인간 백혈구 항원(HLA) 타이핑 이식 시장 점유율 분석
유럽 인간 백혈구 항원(HLA) 이식용 타이핑 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 호흡, 응용 프로그램 우세 및 기술 수명선 곡선이 포함됩니다. 위에 제공된 데이터 포인트는 유럽 인간 백혈구 항원(HLA) 이식용 타이핑 시장과 관련된 회사의 초점에만 관련됩니다.
보고서에서 다루는 주요 기업으로는 Thermo Fisher Scientific Inc., Illumina, Inc., Luminex Corporation, QIAGEN, CareDX, Inc., Immucor Inc., Bio Rad Labaratories, Inc., Takara Bio Inc., BD, Fujirebio, TBG Diagnostics Limited, GenDx 등이 있습니다.
DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 별도로 제공합니다.
또한 전 세계 여러 회사에서 많은 제품 출시와 계약을 체결하여 유럽의 이식용 인간 백혈구 항원(HLA) 타이핑 시장을 더욱 가속화하고 있습니다.
예를 들어,
- 2017년 10월, TBG의 HLAssure SE SBT 키트는 임상 사용을 위해 중국 CFDA 승인을 받았습니다. 이는 중국에서 고해상도 HLA 타이핑 키트에 대한 첫 번째 승인입니다. 이를 통해 회사는 중국에서 입지를 강화하고 시장 성장을 촉진하는 데 도움이 되었습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT & SERVICES LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 AVERAGE PRICE/TEST FOR HLA TYPING BY NEXT GENERATION SEQUENCING (USD)
4.2 PESTEL'S MODEL
4.3 PORTER'S 5 FORCES
5 REGIONAL SUMMARY
5.1 EUROPE
5.1.1 OVERVIEW
6 REGULATORY GUIDELINES FOR EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) FOR TRANSPLANT MARKET
6.1 U.S.
6.2 EUROPE
6.3 JAPAN
6.4 INDIA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING DEMAND FOR ORGAN TRANSPLANT PROCEDURES
7.1.2 GROWING TECHNOLOGICAL ADVANCEMENT & INNOVATIONS IN HLA TYPING
7.1.3 RISING RESEARCH AND DEVELOPMENT ACTIVITIES IN HLA TYPING
7.1.4 INCREASING CERTAIN DISEASES SUCH AS BLOOD CANCERS, AND GENETIC BLOOD DISORDERS
7.2 RESTRAINTS
7.2.1 HIGH COST OF HLA TYPING FOR TRANSPLANTATION PROCEDURE
7.2.2 LIMITED REIMBURSEMENTS POLICIES FOR ORGAN TRANSPLANT
7.3 OPPORTUNITIES
7.3.1 PRODUCT LAUNCHES, AND AGREEMENT BY MAJOR PLAYERS
7.3.2 RISING GOVERNMENT FUNDING FOR ORGAN DONATIONS
7.3.3 RISING PUBLIC AWARENESS FOR ORGAN TRANSPLANTATION
7.4 CHALLENGES
7.4.1 LESS NUMBER OF DONORS FOR ORGAN DONATION
7.4.2 DEARTH OF SKILLED PROFESSIONALS
8 COVID-19 IMPACT ON HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISIONS FOR MANUFACTURERS
8.5 CONCLUSION
9 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES
9.1 OVERVIEW
9.2 INSTRUMENTS
9.3 REAGENTS AND CONSUMABLES
9.4 SOFTWARE & SERVICES
10 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY
10.1 OVERVIEW
10.2 MOLECULAR ASSAY TECHNOLOGIES
10.2.1 SEQUENCING-BASED MOLECULAR ASSAYS
10.2.1.1 NEXT-GENERATION SEQUENCING
10.2.1.2 SANGER SEQUENCING
10.2.1.3 OTHER SEQUENCING-BASED MOLECULAR ASSAYS
10.2.2 PCR-BASED MOLECULAR ASSAYS
10.2.2.1 SEQUENCE-SPECIFIC PRIMER-PCR
10.2.2.2 REAL-TIME PCR
10.2.2.3 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR
10.2.2.4 OTHER PCR-BASED MOLECULAR ASSAYS
10.3 NON-MOLECULAR ASSAY TECHNOLOGIES
11 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE
11.1 OVERVIEW
11.2 SOLID ORGAN TRANSPLANT
11.2.1 KIDNEY
11.2.2 LIVER
11.2.3 HEART
11.2.4 LUNG
11.2.5 PANCREAS
11.2.6 OTHERS
11.3 HEMATOPOIETIC STEM CELL TRANSPLANT
11.3.1 STEM CELL TRANSPLANT
11.3.2 BONE MARROW TRANSPLANT
12 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 DIAGNOSTIC APPLICATIONS
12.2.1 ANTIBODY SCREENING
12.2.2 CHIMERISM MONITORING
12.2.3 OTHERS
12.3 RESEARCH APPLICATIONS
13 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS & TRANSPLANT CENTERS
13.3 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
13.4 INDEPENDENT REFERENCE LABORATORIES
14 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION
14.1 EUROPE
14.1.1 GERMANY
14.1.2 U.K.
14.1.3 FRANCE
14.1.4 ITALY
14.1.5 SPAIN
14.1.6 SWITZERLAND
14.1.7 RUSSIA
14.1.8 NETHERLANDS
14.1.9 TURKEY
14.1.10 BELGIUM
14.1.11 REST OF EUROPE
15 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 MARKET SHARE ANALYSIS: BY TECHNOLOGY
16.1 SEQUENCING BASED MOLECULAR ASSAYS
16.1.1 NORTH AMERICA
16.1.2 EUROPE
16.1.3 ASIA-PACIFIC
16.1.4 SOUTH AMERICA
16.1.5 MIDDLE EAST AND AFRICA
16.2 NGS SEQUENCING
16.2.1 NORTH AMERICA
16.2.2 EUROPE
16.2.3 ASIA-PACIFIC
16.2.4 SOUTH AMERICA
16.2.5 MIDDLE EAST AND AFRICA
16.3 SANGER SEQUENCING
16.3.1 NORTH AMERICA
16.3.2 EUROPE
16.3.3 ASIA-PACIFIC
16.3.4 SOUTH AMERICA
16.3.5 MIDDLE EAST AND AFRICA
16.4 PCR BASED MOLECULAR ASSAYS
16.4.1 NORTH AMERICA
16.4.2 EUROPE
16.4.3 ASIA-PACIFIC
16.4.4 SOUTH AMERICA
16.4.5 MIDDLE EAST AND AFRICA
16.5 REAL TIME PCR
16.5.1 NORTH AMERICA
16.5.2 EUROPE
16.5.3 ASIA-PACIFIC
16.5.4 SOUTH AMERICA
16.5.5 MIDDLE EAST AND AFRICA
16.6 SEQUENCE-SPECIFIC PRIMER-PCR
16.6.1 NORTH AMERICA
16.6.2 EUROPE
16.6.3 ASIA-PACIFIC
16.6.4 SOUTH AMERICA
16.6.5 MIDDLE EAST AND AFRICA
16.7 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR
16.7.1 NORTH AMERICA
16.7.2 EUROPE
16.7.3 ASIA-PACIFIC
16.7.4 SOUTH AMERICA
16.7.5 MIDDLE EAST AND AFRICA
17 COMPANY PROFILE
17.1 THERMO FISHER SCIENTIFIC INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.1.6 SWOT ANALYSIS
17.2 ILLUMINA, INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.2.6 SWOT ANALYSIS
17.3 BIO-RAD LABORATORIES, INC.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.3.6 SWOT ANALYSIS
17.4 QIAGEN
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.4.5.1 ACQUISITION
17.4.6 SWOT ANALYSIS
17.5 ROCHE SEQUENCING (A SUBSIDIARY OF F.HOFFMAN LA-ROCHE LTD.)
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.5.6 SWOT ANALYSIS
17.6 BD
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENTS
17.7 BIOFORTUNA LIMITED
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENT
17.8 CARE DX, INC.
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENTS
17.9 CREATIVE BIOLABS
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.9.3.1 PRODUCT LAUNCH/UPDATE/APPROVAL
17.1 FUJIREBIO
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.10.4.1 CE CERTIFICATION
17.11 GENDX
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENTS
17.12 IMMUCOR, INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.12.3.1 PROUCT LAUNCH
17.13 LUMINEX CORPORATION
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENTS
17.14 OMIXON INC.
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.14.3.1 PRODUCT LAUNCH
17.15 TAKARA BIO INC
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.15.4.1 LICENSING
17.15.5 PRODUCT LAUNCH
17.16 TBG DIAGNOSTICS LIMITED
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
표 목록
TABLE 1 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, AVERAGE PRICE/TEST FOR HLA TYPING BY NEXT GENERATION SEQUENCING
TABLE 2 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BYPRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 3 EUROPE INSTRUMENTS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 EUROPE REAGENTS AND CONSUMABLES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 EUROPE SOFTWARE & SERVICES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 7 EUROPE MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 EUROPE MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY , 2019-2028 (USD MILLION)
TABLE 9 EUROPE SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY , 2019-2028 (USD MILLION)
TABLE 10 EUROPE PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 11 EUROPE NON-MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 13 EUROPE SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 EUROPE SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE , 2019-2028 (USD MILLION)
TABLE 15 EUROPE HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 EUROPE HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 17 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 18 EUROPE DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, REGION, 2019-2028 (USD MILLION)
TABLE 19 EUROPE DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 20 EUROPE RESEARCH APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 22 EUROPE HOSPITALS & TRANSPLANT CENTERS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 EUROPE RESEARCH LABORATORIES & ACADEMIC INSTITUTES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 EUROPE OTHERS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 26 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 27 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 28 EUROPE MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 29 EUROPE SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 30 EUROPE PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 31 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 32 EUROPE SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 33 EUROPE HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 34 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 35 EUROPE DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 36 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 37 GERMANY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 38 GERMANY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 39 GERMANY MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 40 GERMANY SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 41 GERMANY PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 42 GERMANY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 43 GERMANY SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 44 GERMANY HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 45 GERMANY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 46 GERMANY DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 47 GERMANY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 48 U.K. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 49 U.K. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 50 U.K. MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 51 U.K. SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 52 U.K. PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 53 U.K. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 54 U.K. SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 55 U.K. HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 56 U.K. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 57 U.K. DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 58 U.K. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 59 FRANCE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 60 FRANCE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 61 FRANCE MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 62 FRANCE SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 63 FRANCE PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 64 FRANCE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 65 FRANCE SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 66 FRANCE HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 67 FRANCE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 68 FRANCE DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 69 FRANCE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 70 ITALY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 71 ITALY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 72 ITALY MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 73 ITALY SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 74 ITALY PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 75 ITALY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 76 ITALY SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 77 ITALY HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 78 ITALY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 79 ITALY DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 80 ITALY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 81 SPAIN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 82 SPAIN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 83 SPAIN MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 84 SPAIN SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 85 SPAIN PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 86 SPAIN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 87 SPAIN SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 88 SPAIN HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 89 SPAIN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 90 SPAIN DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 91 SPAIN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 92 SWITZERLAND HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 93 SWITZERLAND HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 94 SWITZERLAND MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 95 SWITZERLAND SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 96 SWITZERLAND PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 97 SWITZERLAND HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 98 SWITZERLAND SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 99 SWITZERLAND HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 100 SWITZERLAND HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 101 SWITZERLAND DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 102 SWITZERLAND HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 103 RUSSIA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 104 RUSSIA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 105 RUSSIA MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 106 RUSSIA SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 107 RUSSIA PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 108 RUSSIA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 109 RUSSIA SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 110 RUSSIA HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 111 RUSSIA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 112 RUSSIA DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 113 RUSSIA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 114 NETHERLANDS HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 115 NETHERLANDS HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 116 NETHERLANDS MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 117 NETHERLANDS SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 118 NETHERLANDS PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 119 NETHERLANDS HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 120 NETHERLANDS SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 121 NETHERLANDS HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 122 NETHERLANDS HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 123 NETHERLANDS DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 124 NETHERLANDS HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 125 TURKEY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 126 TURKEY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 127 TURKEY MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 128 TURKEY SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 129 TURKEY PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 130 TURKEY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 131 TURKEY SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 132 TURKEY HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 133 TURKEY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 134 TURKEY DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 135 TURKEY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 136 BELGIUM HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 137 BELGIUM HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 138 BELGIUM MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 139 BELGIUM SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 140 BELGIUM PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 141 BELGIUM HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 142 BELGIUM SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 143 BELGIUM HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 144 BELGIUM HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 145 BELGIUM DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 146 BELGIUM HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 147 REST OF EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
그림 목록
FIGURE 1 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SEGMENTATION
FIGURE 2 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET:
FIGURE 3 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: DROC ANALYSIS
FIGURE 4 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SEGMENTATION
FIGURE 11 INCREASING DEMAND FOR ORGAN TRANSPLANTATION, AND RISING R&D ACTIVITIES IN HLA TYPING ARE EXPECTED TO DRIVE THE EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, AND ASIA-PACIFIC EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET
FIGURE 16 IN 2021, ESTIMATED NEW CASES OF LEUKEMIA, MYELOMA, AND LYMPHOMA IN THE U.S.
FIGURE 17 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, 2020
FIGURE 18 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, 2021-2028 (USD MILLION)
FIGURE 19 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, CAGR (2021-2028)
FIGURE 20 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, LIFELINE CURVE
FIGURE 21 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, 2020
FIGURE 22 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, 2021-2028 (USD MILLION)
FIGURE 23 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, CAGR (2021-2028)
FIGURE 24 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 25 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, 2020
FIGURE 26 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, 2021-2028 (USD MILLION)
FIGURE 27 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, CAGR (2021-2028)
FIGURE 28 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, LIFELINE CURVE
FIGURE 29 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, 2020
FIGURE 30 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 31 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 32 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 33 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY END USERS, 2021-2028 (USD MILLION)
FIGURE 34 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY END USERS, CAGR (2021-2028)
FIGURE 35 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: END USERS, CAGR (2021-2028)
FIGURE 36 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY END USERS, LIFELINE CURVE
FIGURE 37 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SNAPSHOT (2020)
FIGURE 38 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY COUNTRY (2020)
FIGURE 39 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 40 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 41 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCT & SERVICES (2021-2028)
FIGURE 42 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: COMPANY SHARE 2020 (%)
FIGURE 43 NORTH AMERICA SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 44 EUROPE SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 45 ASIA-PACIFIC SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 46 SOUTH AMERICA SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 47 MIDDLE EAST AND AFRICA SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 48 NORTH AMERICA NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 49 EUROPE NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 50 ASIA-PACIFIC NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 51 SOUTH AMERICA NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 52 MIDDLE EAST AND AFRICA NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 53 NORTH AMERICA SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 54 EUROPE SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 55 ASIA-PACIFIC SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 56 SOUTH AMERICA SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 57 MIDDLE EAST AND AFRICA SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 58 NORTH AMERICA PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 59 EUROPE PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 60 ASIA-PACIFIC PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 61 SOUTH AMERICA PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 62 MIDDLE EAST AND AFRICA PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 63 NORTH AMERICA REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 64 EUROPE REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 65 ASIA-PACIFIC REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 66 SOUTH AMERICA REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 67 MIDDLE EAST AND AFRICA REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 68 NORTH AMERICA SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 69 EUROPE SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 70 ASIA-PACIFIC SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 71 SOUTH AMERICA SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 72 MIDDLE EAST AND AFRICA SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 73 NORTH AMERICA SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
FIGURE 74 EUROPE SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
FIGURE 75 ASIA-PACIFIC SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
FIGURE 76 SOUTH AMERICA SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
FIGURE 77 MIDDLE EAST AND AFRICA SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
